LATEST UPDATES » Big Data, Bigger Disease Management and Current preparations to manage the Future Health of Singaporeans       » Big Data in Clinical Research Sector       » Professor Yuk-ling Yung receives Gerard P. Kuiper Prize       » AXA Assistance on Regenerative Medicine       » Singtel – Singapore Cancer Society Race against Cancer 2015       » Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death      
Teva and Takeda to research multiple sclerosis treatment in Japan

Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited have entered an agreement which licenses Takeda the right to commercialize Teva's innovative glatiramer acetate formulation for the treatment of multiple sclerosis, in Japan.

Developed by Teva, glatiramer acetate for injection is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis, including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis. It is considered standard treatment for relapsing-remitting multiple sclerosis, and is now approved in 55 countries worldwide. Teva's glatiramer acetate is designated as an orphan drug in Japan, and currently is under development as an Unapproved New Drug by Teva Pharmaceutical K.K., a subsidiary of Teva, at the request of the Japanese Ministry of Health, Labor and Welfare.

Under the terms of the agreement, Teva will grant Takeda commercialization rights in Japan, and Takeda will submit a New Drug Application for registration of glatiramer acetate in Japan.

Teva and Takeda will work under close cooperation so that both parties can provide a new treatment option to patients with multiple sclerosis in Japan as early as possible, where the current available therapies are still limited.

Source: Business Wire

Click here for the complete issue.

news Runners' High, Happy Feet — If you're Happy, and you know it 'Clap' your Feet
news Snapshot of Stem Cell Expression using Single-cell RNA Sequencing
news A Heroic Voyage — Sydney Brenner's Life in Science
news VeloX, A Minimally Invasive Prosthetic Heart Valve for treating Mitral Regurgitation
news Anti-CD25 monoclonal antibody (90Y-daclizumab) a favorable target towards systemic radio-immunotherapy in Hodgkin's Lymphoma

Credits to Sony Computer Entertainment and click here for behind the scenes.

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy